Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Fineline Cube Dec 31, 2025
Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Fineline Cube Dec 31, 2025
Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Fineline Cube Dec 31, 2025
Company Deals

Ribo Life Science Raises HK$1.6 Billion in Hong Kong IPO for siRNA Pipeline

Fineline Cube Dec 31, 2025
Company Deals

Broncus Medical Acquires Valgen Stake from Venus for $15 Million

Fineline Cube Dec 30, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Fineline Cube Dec 31, 2025
Company Drug

Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy

Fineline Cube Dec 31, 2025
Company Deals

Leadinno Medical Valley Secures Series A+ Funding for Neuroregulation Device R&D

Fineline Cube Oct 25, 2023

Leadinno Medical Valley, a Beijing-based innovator in pain management and neuroregulation devices, has reportedly secured...

Company Drug

China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery

Fineline Cube Oct 25, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...

Company Deals

Gates Foundation Funds CanSino’s Innovative Polio Vaccine Development

Fineline Cube Oct 25, 2023

The Bill & Melinda Gates Foundation has announced a commitment of USD 2 million to...

Company Deals

OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare

Fineline Cube Oct 25, 2023

US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...

Company Deals

BMS Regains Full Rights to Mavacamten in China and Asia from LianBio

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...

Company Drug

Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment

Fineline Cube Oct 25, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...

Company Drug

Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China

Fineline Cube Oct 25, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO

Fineline Cube Oct 24, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...

Company Drug

Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO

Fineline Cube Oct 24, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...

Company Drug

Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine

Fineline Cube Oct 24, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...

Policy / Regulatory

NMPA Implements New Measures for Drug Manufacturing Outsourcing by MAHs

Fineline Cube Oct 24, 2023

The National Medical Products Administration (NMPA) has issued a notice detailing new supervision and management...

Company Drug

Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC

Fineline Cube Oct 24, 2023

Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...

Company Drug

Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion

Fineline Cube Oct 24, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...

Company Drug

Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial

Fineline Cube Oct 24, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607

Fineline Cube Oct 24, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...

Company Medical Device

Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter

Fineline Cube Oct 24, 2023

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...

Company Drug

Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO

Fineline Cube Oct 24, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...

Company Drug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

Fineline Cube Oct 24, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio

Fineline Cube Oct 24, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...

Company Deals

J&J MedTech Partners with CED Medical for Neurointerventional Solutions

Fineline Cube Oct 24, 2023

Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...

Posts pagination

1 … 392 393 394 … 603

Recent updates

  • Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal
  • HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review
  • NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion
  • Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China
  • Sirius Therapeutics Doses First Phase II Patient for SRSD216 siRNA Hyperlipoproteinemia Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Aosaikang Licenses Adlai Nortye’s Pan-RAS Inhibitor AN9025 for China in $100 Million Deal

Company Drug

HutchMed’s Savolitinib NDA Accepted by NMPA for MET-Amplified Gastric Cancer with Priority Review

Company Deals

NeuroGen Pharma Invests RMB 80 Million in GBA Medical Park for Neurology Expansion

Company Deals

Zelgen Licenses ZG006 to AbbVie for $1.2 Billion in Milestones Ex-China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.